Elhusseiny Abdelrahman M, Khodeiry Mohamed M, Liu Xiangxiang, Sayed Mohamed S, Lee Richard K
Harvey and Bernice Jones Eye Institute, University of Arkansas for Medical Sciences, Little Rock, AR.
Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL.
J Glaucoma. 2023 Aug 1;32(8):695-700. doi: 10.1097/IJG.0000000000002237. Epub 2023 May 12.
Slow-coagulation CW-TSCPC is an efficacious, relatively safe, and non-incisional laser treatment option as an initial surgical glaucoma management choice, in secondary aphakic adult glaucoma that is medically uncontrolled.
This study evaluates the outcomes of slow-coagulation continuous wave transscleral cyclophotocoagulation (CW-TSCPC) laser for treating secondary aphakic adult glaucoma after complicated cataract surgery as a primary surgical intervention.
A retrospective chart review of adult aphakic eyes with medically uncontrolled glaucoma underwent slow-coagulation CW-TSCPC as a primary surgical glaucoma intervention was performed. Surgical success was the primary outcome measure. Success was defined as postoperative intraocular pressure (IOP) between 6 and 21 mm Hg with ≥20% reduction compared with baseline and no need for further glaucoma surgeries or development of vision-threatening complications. The secondary outcomes included changes in IOP, glaucoma medication numbers, visual acuity, and postoperative complications during the first year after laser treatment after laser treatment.
This study included 41 eyes of 41 patients. The mean age of study participants was 66.7±13.1 years, with a mean follow-up duration of 19±3.5 months. At one year, the success rate was 63.4%. A statistically significant reduction of the IOP was observed, with the mean IOP decreasing from 29.6±5.8 mm Hg with a mean of 3.9±1.0 medications at baseline to a mean of 19.0±6.4 mm Hg with a mean of 2.5±1.2 medications at 12 months ( P <0.001). Four eyes received CW-TSCPC retreatment, and 2 eyes required incisional glaucoma surgeries. Reported postoperative complications included: visual acuity decline ≥2 lines in 7 eyes, iritis in 6 eyes, hyphema in 5 eyes, cystoid macular edema in 2 eyes, and transient hypotony in 1 eye.
Slow-coagulation CW-TSCPC is an efficacious, relatively safe, and non-incisional laser treatment option as an initial surgical glaucoma management choice, in secondary aphakic adult glaucoma that is medically uncontrolled.
对于药物治疗无法控制的继发性无晶状体成人青光眼，慢凝固连续波经巩膜睫状体光凝术（CW - TSCPC）是一种有效、相对安全且非侵入性的激光治疗选择，可作为青光眼初始手术治疗方案。
本研究评估慢凝固连续波经巩膜睫状体光凝术（CW - TSCPC）激光作为主要手术干预手段治疗复杂白内障手术后继发性无晶状体成人青光眼的效果。
对药物治疗无法控制的青光眼的成人无晶状体眼进行回顾性病历审查，这些患者接受了慢凝固CW - TSCPC作为青光眼主要手术干预。手术成功率是主要结局指标。成功定义为术后眼压（IOP）在6至21毫米汞柱之间，与基线相比降低≥20%，且无需进一步的青光眼手术或出现威胁视力的并发症。次要结局包括激光治疗后第一年眼压、青光眼药物数量、视力和术后并发症的变化。
本研究纳入41例患者的41只眼。研究参与者的平均年龄为66.7±13.1岁，平均随访时间为19±3.5个月。一年时，成功率为63.4%。观察到眼压有统计学意义的降低，平均眼压从基线时的29.6±5.8毫米汞柱（平均使用3.9±1.0种药物）降至12个月时的19.0±6.4毫米汞柱（平均使用2.5±1.2种药物）（P<0.001）。4只眼接受了CW - TSCPC再次治疗，2只眼需要进行青光眼切开手术。报告的术后并发症包括：7只眼视力下降≥2行，6只眼发生虹膜炎，5只眼发生前房积血，2只眼发生黄斑囊样水肿，1只眼发生短暂性低眼压。
对于药物治疗无法控制的继发性无晶状体成人青光眼，慢凝固CW - TSCPC是一种有效、相对安全且非侵入性的激光治疗选择，可作为青光眼初始手术治疗方案。
